TD Asset Management Inc purchased a new position in Rapport Therapeutics (NASDAQ:RAPP - Free Report) in the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund purchased 101,522 shares of the company's stock, valued at approximately $2,361,000. TD Asset Management Inc owned about 0.29% of Rapport Therapeutics at the end of the most recent reporting period.
Analyst Upgrades and Downgrades
Several equities research analysts have recently weighed in on the company. Stifel Nicolaus assumed coverage on Rapport Therapeutics in a research note on Tuesday, July 2nd. They issued a "buy" rating and a $35.00 price objective on the stock. Jefferies Financial Group initiated coverage on Rapport Therapeutics in a research note on Tuesday, July 2nd. They issued a "buy" rating and a $35.00 price target on the stock. Finally, TD Cowen started coverage on Rapport Therapeutics in a report on Tuesday, July 2nd. They set a "buy" rating for the company.
Check Out Our Latest Stock Report on RAPP
Rapport Therapeutics Stock Performance
Shares of Rapport Therapeutics stock traded up $0.09 during trading on Friday, reaching $19.00. 98,644 shares of the company's stock were exchanged, compared to its average volume of 156,739. Rapport Therapeutics has a 1-year low of $16.55 and a 1-year high of $28.08. The company has a 50-day simple moving average of $21.60.
Rapport Therapeutics (NASDAQ:RAPP - Get Free Report) last issued its earnings results on Thursday, August 8th. The company reported ($1.70) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.68) by ($1.02). On average, research analysts forecast that Rapport Therapeutics will post -3.46 earnings per share for the current year.
Insider Activity
In related news, Director James Healy purchased 44,032 shares of the firm's stock in a transaction dated Monday, July 1st. The stock was bought at an average price of $24.52 per share, with a total value of $1,079,664.64. Following the completion of the purchase, the director now owns 40,851 shares in the company, valued at approximately $1,001,666.52. The acquisition was disclosed in a filing with the SEC, which is accessible through this hyperlink.
About Rapport Therapeutics
(
Free Report)
Rapport Therapeutics Inc is a clinical-stage biotechnology company. It focused on discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. Rapport Therapeutics Inc is based in BOSTON.
Featured Articles
Before you consider Rapport Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Rapport Therapeutics wasn't on the list.
While Rapport Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
